Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Eylea (aflibercept intravitreal)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Bayer, Regeneron

Drug class:

VEGF-A inhibitor, PIGF inhibitor

Related drugs:

‹

Cizumab (bevacizumab biosimilar) (0)

Equidacent (bevacizumab biosimilar) (0)

GB222 (bevacizumab biosimilar) (0)

HLX-04 (bevacizumab biosimilar) (0)

ranibizumab (0)

Onbevzi (bevacizumab biosimilar) (0)

Pusintin (bevacizumab biosimilar) (0)

TRS003 (bevacizumab biosimilar) (0)

HD204 (bevacizumab biosimilar) (0)

bevacizumab biosimilar (0)

hVEGF26–104/RFASE (0)

bevacizumab (416)

Aybintio (bevacizumab biosimilar) (14)

bevacizumab-maly (12)

bevacizumab-awwb (11)

bevacizumab-adcd (11)

bevacizumab-tnjn (8)

bevacizumab-bvzr (8)

Krabeva (bevacizumab biosimilar) (7)

Byvasda (bevacizumab biosimilar) (4)

ziv-aflibercept IV (4)

SIBP-04 (bevacizumab biosimilar) (1)

BP102 (bevacizumab biosimilar) (0)

SCT510 (bevacizumab biosimilar) (0)

Ankada (bevacizumab biosimilar) (0)

BI 695502 (bevacizumab biosimilar) (0)

MIL 60 (bevacizumab biosimilar) (0)

LY01008 (bevacizumab biosimilar) (0)

CBT124 (bevacizumab biosimilar) (0)

Cizumab (bevacizumab biosimilar) (0)

Equidacent (bevacizumab biosimilar) (0)

GB222 (bevacizumab biosimilar) (0)

HLX-04 (bevacizumab biosimilar) (0)

ranibizumab (0)

Onbevzi (bevacizumab biosimilar) (0)

Pusintin (bevacizumab biosimilar) (0)

TRS003 (bevacizumab biosimilar) (0)

HD204 (bevacizumab biosimilar) (0)

bevacizumab biosimilar (0)

hVEGF26–104/RFASE (0)

›

MIF overexpression	Glioblastoma	MIF overexpression	Glioblastoma	aflibercept intravitreal Sensitive: C3 – Early Trials aflibercept intravitreal Sensitive : C3	aflibercept intravitreal Sensitive: C3 – Early Trials aflibercept intravitreal Sensitive : C3
CCL27 overexpression	Glioblastoma	CCL27 overexpression	Glioblastoma	aflibercept intravitreal Sensitive: C3 – Early Trials aflibercept intravitreal Sensitive : C3	aflibercept intravitreal Sensitive: C3 – Early Trials aflibercept intravitreal Sensitive : C3
PIGF-L	Glioblastoma	PIGF-L	Glioblastoma	aflibercept intravitreal Sensitive: C3 – Early Trials aflibercept intravitreal Sensitive : C3	aflibercept intravitreal Sensitive: C3 – Early Trials aflibercept intravitreal Sensitive : C3
CXCL10 overexpression	Glioblastoma	CXCL10 overexpression	Glioblastoma	aflibercept intravitreal Sensitive: C3 – Early Trials aflibercept intravitreal Sensitive : C3	aflibercept intravitreal Sensitive: C3 – Early Trials aflibercept intravitreal Sensitive : C3
NRAS mutation	Colorectal Cancer	NRAS mutation	Colorectal Cancer	aflibercept intravitreal Sensitive: C3 – Early Trials aflibercept intravitreal Sensitive : C3	aflibercept intravitreal Sensitive: C3 – Early Trials aflibercept intravitreal Sensitive : C3
KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	aflibercept intravitreal Sensitive: C3 – Early Trials aflibercept intravitreal Sensitive : C3	aflibercept intravitreal Sensitive: C3 – Early Trials aflibercept intravitreal Sensitive : C3
BRAF mutation	Colorectal Cancer	BRAF mutation	Colorectal Cancer	aflibercept intravitreal Sensitive: C3 – Early Trials aflibercept intravitreal Sensitive : C3	aflibercept intravitreal Sensitive: C3 – Early Trials aflibercept intravitreal Sensitive : C3